AP-306

N/A

Report date: 2026/05/23 20:00:57
NME

Base Information

Drug NameAP-306
Drug Alias NameAP-306EOS-789
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium-dependent phosphate transport protein 2B inhibitorsSodium-dependent phosphate transporter 1 inhibitorsSodium-dependent phosphate transporter 2 inhibitors
TargetsSodium-dependent phosphate transport protein 2BSodium-dependent phosphate transporter 1Sodium-dependent phosphate transporter 2
Therapy Area/IndicationsHyperphosphatemiaKidney Failure, ChronicRenal Insufficiency, Chronic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChugai Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAlebund Pharmaceuticals (Hong Kong) LtdR1 Therapeutics IncShanghai Alebund Pharmaceuticals Ltd
Inactive CompaniesChugai Pharmaceutical Co Ltd
Active IndicationsHyperphosphatemiaKidney Failure, ChronicRenal Insufficiency, Chronic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A